Effect of food on the pharmacokinetics of (-) and (+) dOTC when administered as an oral racemate

Journal of Clinical Pharmacology

Volumn 42, Issue 6, 2002, Pages 658-661

  Smith, Patrick F ^a,b   Forrest, Alan ^a   Adams, John M ^c   Ballow, Charles H ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c PharmaResearch Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 3' OXA 4' THIOCYTIDINE; 2' DEOXY 3' OXA THIOCYTIDINE; 2'-DEOXY-3'-OXA-THIOCYTIDINE; DEOXYCYTIDINE; DRUG DERIVATIVE; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; ENANTIOMER; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; NORMAL HUMAN; RACEMIC MIXTURE; RANDOMIZED CONTROLLED TRIAL; AGED; FOOD; MIDDLE AGED; ORAL DRUG ADMINISTRATION; STEREOISOMERISM;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; CROSS-OVER STUDIES; DEOXYCYTIDINE; FOOD; HUMAN; MALE; MIDDLE AGE; REVERSE TRANSCRIPTASE INHIBITORS; STEREOISOMERISM; SUPPORT, NON-U.S. GOV'T; THIONUCLEOSIDES; HUMANS; MIDDLE AGED;

EID: 0036000317     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00970002042006008     Document Type: Article

References (12)

1. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine
2. Potent antiretroviral activity of dOTC (BCH-10652) in HIV-1-infected patients: Initial results from a phase I/II clinical trial [503]
3. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
4. Safety, tolerability, and pharmacokinetics of single oral doses of BCH-10652 in healthy adult males
5. SHAM, a method for biexponential curve resolution using initial slope, height, area and moment of the experimental decay type curve
6. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
7. Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients
8. Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection
9. The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients
10. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS
11. Food-induced reduction in bioavailability of didanosine
12. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal